Project Grant R41AI197550
Award Date 7/7/26
Completion Date 6/30/27
Dollars Obligated $307K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Hastings, NE, USA
Similar Awards
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Massachusetts a $2.64 million Project Grant on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antimicrobial polymers for treating multidrug-resistant wound biofilm infections. The research integrates nanomedicine and computational chemistry to create poly(oxanorborneneimide) antimicrobial polymers (PONI-AMPs) designed to...
- Federal Project Grant Award Summary Gavia Bio, LLC received a $314,363 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 5, 2025, with completion targeted for February 28, 2027. The award supports Phase I preclinical development of DGL13K, a patented antimicrobial peptide designed as a novel topical treatment for drug-resistant burn wound infections. This research...
- Federal Project Grant Award Summary Fimbrion Therapeutics Inc. received a $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 15, 2025, with completion targeted for July 31, 2027. The award funds the development of small molecule glycoside inhibitors targeting LecB, a bacterial lectin protein essential to Pseudomonas aeruginosa biofilm formation and...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $417,845 to the University of Nebraska Medical Center under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 9, 2025, for a project period extending through June 30, 2027. The award supports research to identify novel immune determinants influencing Staphylococcus aureus biofilm infection using Collaborative Cross (CC) mouse lines. The research addresses gaps in...
- Federal Project Grant Award Summary The University of Nebraska Medical Center (UNMC) received a $762,758 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 24, 2026, with a completion date of May 31, 2031. The project develops bioengineered scaffolds to treat post-craniotomy Staphylococcus aureus biofilm infections, a significant clinical challenge affecting nearly 1 million...
- Federal Grant Award Summary Life Pharms Inc. received a $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 19, 2025, with a completion date of August 31, 2027. The award supports the development of LP10581, a novel antifungal compound designed to address the critical public health crisis of drug-resistant invasive fungal infections. LP10581 is a...
- Federal Grant Award Summary Fesariustherapeutics Inc. received a $349,892 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025 through August 31, 2027. The company is developing DermisphereShield, an antimicrobial dermal regeneration template designed to address wound healing complications in contaminated or resource-constrained clinical environments. The product...
- Federal Grant Award Summary Microbiotix, Inc. received a $299,946 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 22, 2025, with an ultimate completion date of August 31, 2027. The grant supports the development of novel benzyl-piperidine (BP) antifungal agents to treat intractable mucormycosis infections caused by Mucorales fungi, a WHO-designated...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Southern California $835,021 on July 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize trained innate immunity mediated by a novel immunomodulatory mixture. The research focuses on developing and optimizing a protein-free combination of aluminum hydroxide, monophosphoryl lipid, and fungal mannan to prevent hospital-acquired...
- Federal Project Grant Award Summary Shy Therapeutics, LLC received a $300,616 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 1, 2025, through August 31, 2027. The award supports the development of a novel class of antifungal small-molecule therapeutics designed to address the global health burden posed by drug-resistant fungal infections. The project focuses on...